2006/N 09/754,775

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

licant:

David J. Grainger et al.

Examiner:

Theodore Criares

Serial No.:

09/754,775

Group Art Unit:

1617

Filed:

January 4, 2001

Docket:

295.009US3

Title:

PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH

TAMOXIFEN ANALOGUES

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Respectfully submitted, DAVID J. GRAINGER ET AL. By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date

\_\_\_\_ By .

Janet E. Embretson Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this \_\_\_\_\_\_ day of April, 2002.

PUW 1110

Signatule